As global oncology enters a new era of immunotherapy and cell-based treatments, traditional precision medicine tools focused solely on genomic alterations have proven insufficient for accurately predicting therapeutic outcomes. In response to the 2025 American Association for Cancer Research (AACR) spotlight on tumor evolution and the tumor immune microenvironment (TiME), a Taiwan-based research team has introduced the Personalized Precision Oncology and Tumor Immune Microenvironment Monitoring Platform, offering clinical and drug development teams a more realistic and actionable view of immune dynamics.

This platform integrates real-time liquid biopsy, immune cell activity analysis, and preliminary TIL selection technologies. It is positioned as a research-use and clinical decision-support tool to assist in immunotherapy and cell therapy strategy development. By profiling immune–tumor interactions at the cellular level, it fills key gaps left by conventional sequencing-based methods.

Addressing Unmet Needs in the Global Precision Oncology Landscape

At the 2025 AACR Annual Meeting, experts emphasized that changes in the tumor immune microenvironment and cellular heterogeneity are becoming critical indicators for therapeutic prediction. This platform is aligned with that consensus, providing dynamic, operable, and quantifiable data at the cellular level, enabling both clinical and R&D teams to strengthen therapeutic decision-making frameworks.

Target Users and Collaboration Opportunities

This platform is particularly suited for:

• Companies developing immunotherapies and cell-based therapies
• Medical institutions conducting personalized oncology research
• Research teams exploring next-generation immune response biomarkers and TIL selection strategies

Platform Use Disclaimer

This platform is intended for research or clinical support use only and is not a substitute for diagnosis or treatment. All results are for physician reference only. Final clinical decisions should be made by healthcare professionals based on comprehensive diagnostic information.